Irbepress Plus (Hydrochlorothiazide, Irbesartan)

Irbesartan blocks the AT1 receptor, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. Hydrochlorothiazide acts on the distal convoluted tubule to inhibit sodium‑chloride reabsorption, promoting diuresis. Together they lower peripheral resistance and plasma volume, resulting in reduced blood pressure.

The dosage of Irbepress Plus is individualized by the prescribing clinician based on the patient’s blood pressure, renal function, and overall health status. The prescriber determines the appropriate strength and frequency according to current clinical guidelines.

Irbepress Plus is classified as Pregnancy Category D, indicating evidence of risk to the fetus and it should be avoided in pregnant women. It is also not recommended during breastfeeding because the active ingredients can be excreted in breast milk and may affect the infant.

To order Irbepress Plus, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with single‑agent therapies, Irbepress Plus offers the convenience of two mechanisms in one tablet, often achieving better blood pressure control with fewer pills. It may be preferred over monotherapy when a patient requires both vasodilation and diuresis, but clinicians consider individual tolerability and comorbidities when selecting therapy.

Irbepress Plus tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Irbepress Plus is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a full glass of water and follow any specific timing instructions provided by the healthcare professional.

Serious risks include severe allergic reactions, marked hypotension, acute kidney injury, and significant electrolyte disturbances such as hyperkalemia or hyponatremia. Patients should seek immediate medical attention if they experience symptoms like swelling, difficulty breathing, sudden dizziness, or persistent weakness.

Irbepress Plus should not be used by individuals with known hypersensitivity to irbesartan, hydrochlorothiazide, or any component of the formulation. It is also contraindicated in pregnant women, patients with severe renal impairment, and those taking potassium‑sparing diuretics or supplements that could cause dangerous hyperkalemia.